ATE345115T1 - Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten - Google Patents

Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten

Info

Publication number
ATE345115T1
ATE345115T1 AT99928901T AT99928901T ATE345115T1 AT E345115 T1 ATE345115 T1 AT E345115T1 AT 99928901 T AT99928901 T AT 99928901T AT 99928901 T AT99928901 T AT 99928901T AT E345115 T1 ATE345115 T1 AT E345115T1
Authority
AT
Austria
Prior art keywords
treatment
compositions
chlamydial
associated diseases
trimoxazole
Prior art date
Application number
AT99928901T
Other languages
English (en)
Inventor
Karl William Baumgart
Highway Pacific
Thomas Julius Borody
Original Assignee
Karl William Baumgart
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl William Baumgart, Borody Thomas J filed Critical Karl William Baumgart
Application granted granted Critical
Publication of ATE345115T1 publication Critical patent/ATE345115T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99928901T 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten ATE345115T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease

Publications (1)

Publication Number Publication Date
ATE345115T1 true ATE345115T1 (de) 2006-12-15

Family

ID=3808619

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928901T ATE345115T1 (de) 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten

Country Status (10)

Country Link
US (1) US6475518B1 (de)
EP (2) EP1754472B1 (de)
JP (3) JP4651816B2 (de)
AT (1) ATE345115T1 (de)
AU (2) AUPP437698A0 (de)
CA (2) CA2684402C (de)
DE (1) DE69934010T2 (de)
ES (2) ES2514469T3 (de)
NZ (1) NZ509504A (de)
WO (1) WO2000001378A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
AU3760400A (en) * 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
AU3984101A (en) * 2000-02-24 2001-09-03 Advanced Pharma Inc Antibiotic and antifungal compositions
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
PL201686B1 (pl) * 2000-03-22 2009-04-30 Upjohn Co Sprasowana tabletka i zastosowanie linezolidu oraz substancji pomocniczych do wytwarzania sprasowanej tabletki
IT1318459B1 (it) * 2000-04-11 2003-08-25 Zambon Spa Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (de) * 2001-05-30 2002-12-04 New Pharma Research Sweden AB Synergistische Antibiotika-enthaltende Zusammensetzungen
NZ530845A (en) * 2001-07-06 2006-03-31 Sucampo Ag Composition for topical administration
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
WO2003075852A2 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceuticals Corporation Antibiotic composition
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
EP1531828A4 (de) * 2002-05-23 2005-11-02 Activbiotics Inc Verfahren zur behandlung von bakterieninfektionen und damit zusammenhängenden erkrankungen
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
EP1575567A4 (de) * 2002-12-12 2008-10-08 Activbiotics Inc Verfahren und reagentien zur behandlungoder vorbeugung von arteriosklerose und damit einhergehenden krankheiten
WO2004054513A2 (en) * 2002-12-12 2004-07-01 Activbiotics, Inc. Methods and compositions for treating and preventing ear infections
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) * 2003-08-11 2005-06-20 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
EP2361620B1 (de) 2004-02-06 2016-04-06 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
JP5009152B2 (ja) * 2004-05-28 2012-08-22 サリックス ファーマシューティカルズ, インコーポレイテッド 放射線誘発性腸炎の予防、処置、および回復
EA016776B9 (ru) 2004-09-30 2012-11-30 Ковалон Текнолоджиз Инк. Неадгезивные эластичные желатиновые матрицы
WO2006057429A1 (ja) * 2004-11-24 2006-06-01 Nanocarrier Co., Ltd. ブロックコポリマーのモーフォロジ-の変化方法
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
NZ603744A (en) * 2005-08-24 2014-06-27 Salix Pharmaceuticals Inc Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
WO2009015214A2 (en) * 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
GB2548296A (en) 2009-10-22 2017-09-13 Borody Thomas J Novel parasite therapy
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
AU2011245455A1 (en) 2010-04-26 2012-11-15 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
CA2821196C (en) 2010-12-13 2022-11-22 Thomas Julius Borody Gastric and colonic formulations and methods for making and using them
US9376364B2 (en) * 2011-08-16 2016-06-28 Purac Biochem B.V. Acid/salt separation
PT2877163T (pt) 2012-07-27 2019-05-24 Redhill Biopharma Ltd Formulações e métodos de fabrico de formulações para utilização na evacuação colónica
EP2968281B1 (de) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor-hemmer zur vorbeugung von darmpolypenwachstum
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
JP6963545B2 (ja) 2015-10-06 2021-11-10 レッド ヒル バイオファーマ リミテッドRedHill Biopharma Ltd. 癌を治療するための併用療法
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
EP3612187B1 (de) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c und doxycyclin: eine synthetische letale kombinationstherapie zur eradikation von krebsstammzellen (cscs)
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CU20190092A7 (es) 2017-05-19 2020-10-20 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
US20210052557A1 (en) * 2018-02-01 2021-02-25 Centre For Digestive Diseases Compositions for treating infective arterial diseases and related conditions
RU2684728C1 (ru) * 2018-05-21 2019-04-12 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
EP4125898A1 (de) * 2020-03-27 2023-02-08 Vectura Limited Zusammensetzungen zur behandlung einer atemwegserkrankung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588550A (en) 1897-08-24 Alarm-clock
GB1463550A (en) 1974-08-06 1977-02-02 Bodrero G Pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI883067A7 (fi) * 1988-06-27 1989-12-28 Labsystems Oy Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) * 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

Also Published As

Publication number Publication date
DE69934010D1 (de) 2006-12-28
WO2000001378A1 (en) 2000-01-13
EP1754472B1 (de) 2014-07-23
NZ509504A (en) 2004-04-30
ES2514469T3 (es) 2014-10-28
CA2336593C (en) 2010-06-29
JP2013147504A (ja) 2013-08-01
EP1093363B1 (de) 2006-11-15
CA2684402C (en) 2012-10-30
JP2002519374A (ja) 2002-07-02
JP2010174030A (ja) 2010-08-12
JP4651816B2 (ja) 2011-03-16
DE69934010T2 (de) 2007-06-21
EP1754472A2 (de) 2007-02-21
AU757293B2 (en) 2003-02-13
CA2336593A1 (en) 2000-01-13
EP1093363A4 (de) 2003-09-24
EP1754472A3 (de) 2009-08-26
AUPP437698A0 (en) 1998-07-23
CA2684402A1 (en) 2000-01-13
EP1093363A1 (de) 2001-04-25
HK1037864A1 (en) 2002-02-22
JP5335726B2 (ja) 2013-11-06
AU4591999A (en) 2000-01-24
ES2278449T3 (es) 2007-08-01
US6475518B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
ATE345115T1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
ATE316786T1 (de) Behandlung von mukositis
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE279942T1 (de) Mehrwertige impstoffzusammensetzung mit gemischten trägern
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
DE69825128D1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
BR0111989A (pt) Peptìdeos, composições e processos para o tratamento de burkholderia cepacia
PT775745E (pt) Aptameros inibidores de catepsina g
DE69613975D1 (de) Dialkyltiacumicine
DK1763339T3 (da) Orale antimikrobielle farmaceutiske præparater
ID25478A (id) Agonis 5-ht1f
ATE260097T1 (de) Hopfensäuren zur hemmung von staphylococcus aureus
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
EP1496742A4 (de) Verwendung von nichtantibakteriellen tetrazyklin-analoga und ihren formulierungen für die behandlung von bakteriellen exotoxinen
DE69935662D1 (de) Mittel zur prävention/behandlung entzündlicher darmerkrankungen
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE212229T1 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
ATE263556T1 (de) Phenylessigsäure enthaltende zusammensetzungen zur behandlung und vorbeugung der atherosklerose und der restenose
SE9902673D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties